Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) Price Target at $45.00

Shares of Silence Therapeutics plc (NASDAQ:SLN) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $40.67.

A number of analysts have weighed in on SLN shares. The Goldman Sachs Group lowered their target price on Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a report on Tuesday. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, January 29th. Chardan Capital restated a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th. Finally, Morgan Stanley decreased their price objective on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday.

Institutional Trading of Silence Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SLN. Woodline Partners LP increased its position in shares of Silence Therapeutics by 22.6% in the 4th quarter. Woodline Partners LP now owns 498,732 shares of the company’s stock valued at $3,431,000 after acquiring an additional 91,829 shares during the period. Two Sigma Advisers LP increased its position in shares of Silence Therapeutics by 18.6% in the 4th quarter. Two Sigma Advisers LP now owns 98,800 shares of the company’s stock valued at $680,000 after acquiring an additional 15,500 shares during the period. Redmile Group LLC increased its position in shares of Silence Therapeutics by 26.3% in the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock valued at $16,507,000 after acquiring an additional 500,000 shares during the period. Point72 Asset Management L.P. increased its position in shares of Silence Therapeutics by 35.3% in the 4th quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock valued at $4,356,000 after acquiring an additional 165,300 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Silence Therapeutics by 50.5% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 128,990 shares of the company’s stock valued at $887,000 after acquiring an additional 43,289 shares during the period. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Stock Up 5.6 %

Silence Therapeutics stock opened at $4.73 on Thursday. The business has a fifty day moving average of $5.49 and a two-hundred day moving average of $11.53. The firm has a market cap of $141.57 million, a P/E ratio of -3.01 and a beta of 1.05. Silence Therapeutics has a twelve month low of $4.06 and a twelve month high of $27.72.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.